Global Immunology Drugs Market Growth, Trends and Developments, Opportunities to 2023

"The Latest Research Report Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

Immune-mediated inflammatory diseases are a common set of chronic disorders that affect 5-7% of people in Western populations.

Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response.

This report covers all immunological disorders, but there is a particular focus on four key diseases, rheumatoid arthritis, psoriasis, inflammatory bowel disease and graft versus host disease/transplant rejection, as these conditions have the largest pipelines within the therapy area.

The market size for immunology therapeutics was valued at $65.1 billion in 2016 and it is expected to grow at a compound annual growth rate (CAGR) of 8.2% to $113 billion in 2023.

Get Sample Copy of this report @ https://www.marketresearchreports.biz/sample/sample/1769909

Scope

The immunology market landscape is expected to change. Biosimilar competition is expected to affect the revenue of the big blockbuster drugs, and novel targets are expected to enter the market and drive market growth.
Overall, there are 2,070 immunology products in the pipeline.
Which molecular targets are most prominent within the pipeline?
How do the key indications differ in terms of molecule type?
How does the composition of the pipeline compare with that of the existing market?
What mechanisms of action are most common for pipeline drugs?
The market size for immunology therapeutics is expected to grow, from $65.1 billion in 2016 to $113 billion in 2023, at a CAGR of 8.2%.
Which products will contribute to market growth most, and which will achieve blockbuster status?
Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?
What CAGR will these companies register in the forecast period?
How many strategic consolidations have been completed in the past decade?
Which types of assets attract the largest deal values?

Reasons to buy

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the four key indications.
Visualize the composition of the immunology market overall and across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological conditions.
Identify trends and developments, in terms of molecule type and molecular target, within the overall immunology pipeline, as well as for each of the four key indications.
Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.
Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
Recognize how the evolving treatment landscape will drive market growth to 2023 and understand the contributions that different products, molecular targets and companies will make to this growth.
Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals.

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/1769909

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 12
2.1 Therapy Area Overview 12
2.1.1 Rheumatoid Arthritis 12
2.1.2 Psoriasis 13
2.1.3 Inflammatory Bowel Disease 14
2.1.4 Graft Versus Host Disease and Transplant Rejection 15
2.2 Symptoms 16
2.3 Diagnosis 19
2.3.1 Rheumatoid Arthritis 19
2.3.2 Psoriasis 19
2.3.3 Inflammatory Bowel Disease 19
2.3.4 Graft Versus Host Disease and Transplant Rejection 20
2.4 Etiology and Pathophysiology 20
2.4.1 Rheumatoid Arthritis 23
2.4.2 Psoriasis 24
2.4.3 Inflammatory Bowel Disease 25
2.4.4 Graft Versus Host Disease and Transplant Rejection 26
2.5 Epidemiology 27
2.5.1 Rheumatoid Arthritis 28
2.5.2 Psoriasis 28
2.5.3 Inflammatory Bowel Disease 29
2.5.4 Graft Versus Host Disease and Transplant Rejection 31
2.6 Co-morbidities and Complications 31
2.7 Treatment 32
2.7.1 Rheumatoid Arthritis 33
2.7.2 Psoriasis 35
2.7.3 Inflammatory Bowel Disease 36
2.7.4 Graft-Versus-Host Disease and Transplant Rejection 37

3 Key Marketed Products 40
3.1 Overview 40
3.2 Humira (adalimumab) - AbbVie 41
3.3 Enbrel (etanercept) - Amgen 43
3.4 Remicade (infliximab) - Johnson & Johnson 45
3.5 Rituxan (rituximab) - Roche 48
3.6 Stelara (ustekinumab) - Johnson & Johnson 50
3.7 Simponi (golimumab) - Johnson & Johnson 52
3.8 Orencia (abatacept) - Bristol-Myers Squibb 54
3.9 Tysabri (natalizumab) - Biogen 56
3.10 Actemra (tocilizumab) - Roche 58
3.11 Prograf (tacrolimus) - Astellas 60
3.12 Cimzia (certolizumab) - UCB 62
3.13 Entyvio (vedolizumab) - Takeda 64
3.14 Cosentyx (secukinumab) - Novartis 65
3.15 Otezla (apremilast) - Celgene 67
3.16 Xeljanz (tofacitinib) - Pfizer 68
3.17 Taltz (ixekizumab) - Eli Lilly 70

4 Pipeline Landscape Assessment 72
4.1 Overview 72
4.2 Pipeline Development Landscape 72
4.3 Molecular Targets in the Pipeline 76
4.4 Clinical Trials Landscape 79
4.4.1 Clinical Trial Failure Rates 80
4.4.2 Clinical Trial Duration 82
4.4.3 Clinical Trial Size 86
4.4.4 Cumulative Clinical Program Size 90
4.5 Assessment of Key Late-Stage Pipeline Products 93
4.5.1 Filgotinib - Galapagos and Gilead Sciences 93
4.5.2 AR-101 - Aimmune Therapeutics 94
4.5.3 Upadacitinib tartrate - AbbVie 95
4.5.4 Lanadelumab - Shire 97
4.5.5 Ozanimod hydrochloride - Celgene 98
4.5.6 Risankizumab - AbbVie 99
4.6 Conclusion 101

5 Multi-scenario Market Forecast to 2023 102
5.1 Overall Market Size 102
5.2 Generic Penetration 104
5.3 Revenue Forecast by Molecular Target 105
5.3.1 Cytokines and Cytokine Receptors 106
5.3.2 Intracellular Signal Transducers 107
5.3.3 Cell Surface Antigens 108
5.3.4 Intercellular Interaction and Adhesion Molecules 109

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.